Middle meningeal artery embolization
Sponsors
Chinese University of Hong Kong, University Hospital, Montpellier, The Affiliated Hospital Of Guizhou Medical University, Cerenovus, Part of DePuy Synthes Products, Inc., Kazutaka Uchida
Conditions
Brain DiseasesCentral Nervous System DiseasesChronic Migraine HeadacheChronic Subdural HematomaChronic Subdural HematomasEndovascular TreatmentHematoma, Subdural, ChronicMiddle Meningeal Artery Embolization
Unknown Phase
Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma
WithdrawnNCT04500795
Start: 2024-01-01End: 2027-03-31Updated: 2024-02-21
The Onyx™ Trial For The Embolization Of The Middle Meningeal Artery For Chronic Subdural Hematoma
TerminatedNCT04742920
Start: 2021-10-12End: 2025-05-28Updated: 2025-07-15
Efficacy and Safety of Middle Meningeal Artery Embolization for Treatment of Intractable Migraine
CompletedNCT06029153
Start: 2023-06-15End: 2024-11-30Updated: 2024-12-31
MMA Embolization for Refractory Chronic Migraine
RecruitingNCT06735833
Start: 2025-04-23End: 2029-07-31Target: 70Updated: 2026-08-28
Middle Meningeal Artery Embolization for Patients With Chronic Subdural Hematoma
RecruitingNCT06772740
Start: 2024-12-23End: 2029-03-31Target: 600Updated: 2026-07-17
Middle Meningeal Artery Embolization for Chronic Migraine
WithdrawnNCT07044648
Start: 2026-02-01End: 2027-08-01Updated: 2026-02-06
Prospective MMA Embolization Registry
Not yet recruitingNCT07626671
Start: 2026-07-01End: 2028-01-31Target: 100Updated: 2026-06-04
Safety and Efficacy of Middle Meningeal Artery Embolization for the Treatment of Migraine.
Not yet recruitingNCT07633067
Start: 2026-06-15End: 2028-12-31Target: 150Updated: 2026-06-08
EMBRACE-OBS: Single-Site Observational Registry of Patient-Reported Outcomes Following MMA Embolization for Migraine
Not yet recruitingNCT07652034
Start: 2026-07-01End: 2028-06-01Target: 50Updated: 2026-06-18
Middle Meningeal Artery Embolization in Patients With Chronic Subdural Hematoma
Not yet recruitingNCT07806552
Start: 2026-09-01End: 2029-02-28Target: 35Updated: 2026-09-08